Independent directory Public ClinicalTrials.gov records United States
Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 22, 2026, 4:52 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1537–1560 of 30,991 matching trials from the live ClinicalTrials.gov search.
Conditions
Glioblastoma, Glioblastoma, IDH-wildtype, Glioblastoma IDH (Isocitrate Dehydrogenase) Wildtype
Interventions
NeuroBlate® Laser Ablation Laser Interstitial Thermal Therapy, Cemiplimab, Chemotherapy
Device · Drug
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older
Enrollment
99 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2032
U.S. locations
2
States / cities
Rochester, Minnesota • St Louis, Missouri
Conditions
Trichotillomania
Interventions
Keen2 Predictive Awareness Bracelet
Behavioral
Lead sponsor
HabitAware Inc.
Industry
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
Kent, Ohio
Completed Not applicable Interventional Accepts healthy volunteers Results available

Study of the Anti-Inflammatory Effects of Colgate Total® During an Experimental Gingivitis Model

NCT01799226
Conditions
Gingivitis
Interventions
Toothpaste without triclosan, Triclosan
Other
Lead sponsor
University of Michigan
Other
Eligibility
18 Years to 40 Years
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013
U.S. locations
1
States / cities
Ann Arbor, Michigan
Completed Phase 2 Interventional Results available

Ruxolitinib for Premalignant Breast Disease

NCT02928978
Conditions
Ductal Carcinoma In Situ, Atypical Lobular Hyperplasia, Atypical Ductal Hyperplasia, Lobular Carcinoma In Situ
Interventions
Ruxolitinib, Placebo (for Ruxolitinib)
Drug
Lead sponsor
Julie Nangia
Other
Eligibility
18 Years and older
Enrollment
84 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2024
U.S. locations
8
States / cities
Birmingham, Alabama • Indianapolis, Indiana • The Bronx, New York + 3 more
Conditions
Ovarian Cancer, Peritoneal Cancer, Fallopian Tube Cancer
Interventions
Mirvetuximab soravtansine plus Bevacizumab, Bevacizumab
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years and older · Female only
Enrollment
520 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2032
U.S. locations
74
States / cities
Mobile, Alabama • Phoenix, Arizona • Irvine, California + 62 more
Conditions
Major Depressive Disorder, Irritable Bowel Syndrome
Interventions
Ganeden BC30, Placebo (sugar pill), Ganeden BC30, Placebo (sugar pill)
Drug · Other
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 65 Years
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
2
States / cities
Burlington, Massachusetts • Westborough, Massachusetts
Conditions
Metastatic Uveal Melanoma
Interventions
IDE196, Crizotinib, Pembrolizumab, Ipilimumab, Nivolumab, Dacarbazine
Drug
Lead sponsor
IDEAYA Biosciences
Industry
Eligibility
18 Years and older
Enrollment
420 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
31
States / cities
Scottsdale, Arizona • La Jolla, California • Los Angeles, California + 23 more
Conditions
Advanced Lung Non-Small Cell Carcinoma, Recurrent Lung Non-Small Cell Carcinoma, Stage III Lung Cancer AJCC v8, Stage IIIA Lung Cancer AJCC v8, Stage IIIB Lung Cancer AJCC v8, Stage IIIC Lung Cancer AJCC v8, Stage IV Lung Cancer AJCC v8, Stage IVA Lung Cancer AJCC v8, Stage IVB Lung Cancer AJCC v8
Interventions
Cobalamin, Dexamethasone, Docetaxel, Folic Acid, Gemcitabine, Nogapendekin Alfa, Pembrolizumab, Pemetrexed, Ramucirumab
Dietary Supplement · Drug · Biological
Lead sponsor
SWOG Cancer Research Network
Network
Eligibility
Not listed
Enrollment
82 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
350
States / cities
Birmingham, Alabama • Goodyear, Arizona • Little Rock, Arkansas + 280 more
Conditions
HIV
Interventions
HIV knowledge Intervention
Behavioral
Lead sponsor
University of California, Los Angeles
Other
Eligibility
18 Years to 100 Years · Male only
Enrollment
558 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2015
U.S. locations
1
States / cities
Los Angeles, California
Conditions
Chronic Kidney Disease (CKD) With Diabetes Mellitus (DM), CKD Stage 3, CKD Stage 4, CKD Stage 5, Diabetes Mellitus, Diabetic Kidney Disease
Interventions
PLAFOND diet
Dietary Supplement
Lead sponsor
University of California, Irvine
Other
Eligibility
18 Years and older
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
2
States / cities
Orange, California • Torrance, California
Conditions
Depressive Disorder, Depression
Interventions
Telephone cognitive behavioral therapy
Behavioral
Lead sponsor
US Department of Veterans Affairs
Federal
Eligibility
18 Years and older
Enrollment
85 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2010
U.S. locations
3
States / cities
San Francisco, California • Hines, Illinois
Completed Phase 3 Interventional Results available

Study of Eteplirsen in DMD Patients

NCT02255552
Conditions
Duchenne Muscular Dystrophy (DMD)
Interventions
eteplirsen
Drug
Lead sponsor
Sarepta Therapeutics, Inc.
Industry
Eligibility
7 Years to 16 Years · Male only
Enrollment
109 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2019
U.S. locations
37
States / cities
Phoenix, Arizona • Los Angeles, California • Sacramento, California + 32 more
Completed Phase 4 Interventional Results available

EVOLVE Short DAPT Study

NCT02605447
Conditions
Coronary Artery Disease
Interventions
3 months of dual antiplatelet therapy (DAPT), SYNERGY Stent System
Drug · Device
Lead sponsor
Boston Scientific Corporation
Industry
Eligibility
18 Years and older
Enrollment
2,009 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
89
States / cities
Phoenix, Arizona • Little Rock, Arkansas • Bakersfield, California + 75 more
Completed Not applicable Interventional Accepts healthy volunteers Results available

The R4R Advance Care Planning Pilot Study

NCT06129149
Conditions
Advance Care Planning
Interventions
Trauma-Informed Care-adapted and Checklist-guided ACP intervention
Behavioral
Lead sponsor
Vanderbilt University
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024
U.S. locations
1
States / cities
Nashville, Tennessee
Conditions
Non-Small Cell Lung Cancer, EGFR Mutation, Metastatic Lung Cancer, MET Alteration
Interventions
ANS014004 + PLB1004, ANS014004 + Osimertinib
Drug
Lead sponsor
Beijing Pearl Biotechnology Limited Liability Company
Industry
Eligibility
18 Years and older
Enrollment
253 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
1
States / cities
New York, New York
Conditions
Multiple Myeloma
Interventions
Ixazomib, Melphalan, Prednisone
Drug
Lead sponsor
Millennium Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
61 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2016
U.S. locations
2
States / cities
Lebanon, New Hampshire • Morgantown, West Virginia
Conditions
Prediabetes
Interventions
non-sugar sweeteners - Sucralose, non-sugar sweetener - aspartame, Non-sugar sweetener - control
Other
Lead sponsor
Virginia Polytechnic Institute and State University
Other
Eligibility
40 Years and older
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
1
States / cities
Blacksburg, Virginia
Conditions
NMIBC, MIBC, Muscle Invasive Bladder Cancer (MIBC), Non Muscle Invasive Bladder Cancer
Interventions
This is a non-interventional, observational, prospective study.
Other
Lead sponsor
Bladder Cancer Advocacy Network
Other
Eligibility
18 Years and older
Enrollment
1,400 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2027 – 2032
U.S. locations
1
States / cities
Dallas, Texas
Conditions
Allergic Conjunctivitis of Both Eyes
Interventions
TL-925, Placebo
Drug
Lead sponsor
Telios Pharma, Inc.
Industry
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Andover, Massachusetts
Conditions
Erectile Dysfunction
Interventions
Double-S
Device
Lead sponsor
Stanford University
Other
Eligibility
18 Years and older · Male only
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
1
States / cities
Stanford, California
Conditions
Lymphoma, Non-Hodgkin, Multiple Myeloma
Interventions
G-CSF and plerixafor
Drug
Lead sponsor
Genzyme, a Sanofi Company
Industry
Eligibility
18 Years to 70 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2006
U.S. locations
5
States / cities
Duarte, California • Beech Grove, Indiana • Rochester, New York + 2 more
Conditions
Prediabetes
Interventions
No-carrageenan diet, Regular Diet
Other
Lead sponsor
University of Illinois Chicago
Other
Eligibility
18 Years and older
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
1
States / cities
Chicago, Illinois
Conditions
Alzheimer Disease
Interventions
Real-time Group Video, Enhanced Usual Care
Behavioral
Lead sponsor
University of Kansas
Other
Eligibility
55 Years and older
Enrollment
198 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
1
States / cities
Lawrence, Kansas
Completed Phase 2 Interventional Results available

Trial of High-Dose Rifampin in Patients With TB

NCT01408914
Conditions
Tuberculosis
Interventions
Higher-Dose Rifampin
Drug
Lead sponsor
Harvard University Faculty of Medicine
Other
Eligibility
18 Years to 60 Years
Enrollment
180 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
1
States / cities
Gainesville, Florida